Business Activities
Research and Development
Research
Mochida's Pharmaceutical Research Center - targeting diabetes and obesity as its core fields and chronic pain as another important field of study - is immersed in efforts to discover and synthesize promising low-molecular weight compounds, using state-of-the-art computer-screening, high-throughput screening, and other advanced methods
As a member of the Pharmaceutical Consortium for Protein Structure Analysis since 2002, the Center has clarified the three-dimensional structure of proteins utilizing the "SPring-8" synchrotron radiation facility.
Development
Mochida Pharmaceutical's product development pipelines offer lineups that will greatly enhance our four major specialities: cardiovascular medicine, obstetrics and gynecology, dermatology, emergency medicine, and psychiatry. We remain ever committed to the efficient development of new and widely hoped-for therapeutic drugs, to be put to medical use as soon as is safely possible.
Pipeline
| Code | Name | Indications | Formulation | Stage | Remarks |
|---|---|---|---|---|---|
| FSK0808 | G-CSF | Neutropenia | Injection | Filed | Biosimilar （Follow-on biologics) Co-development with Fuji Pharma |
| MD-0901 | mesalazine | Ulcerative colitis | Oral | Phase III | Licensed-in from Shire Pharmaceuticals Group （UK） |
| AJH801 | cilnidipine/valsartan combination | Hypertension | Oral | Phase III | Co-development with Ajinomoto Pharmaceuticals |
| MD-0701 | treprostinil | Pulmonary arterial hypertension | Injection | Phase II/III | Originator: United Therapeutics (USA) |
| MND-21 | ethyl icosapentate | Non-alcoholic steatohepatitis | Oral | Phase II | |
| MJR-35 | dienogest | Uterine adenomyosis | Oral | Early Phase II |